Mon, Dec 29, 2014, 11:23 AM EST - U.S. Markets close in 4 hrs 37 mins

Recent

% | $
Quotes you view appear here for quick access.

Immune Pharmaceuticals, Inc. Message Board

  • jonaustin1481 jonaustin1481 May 1, 2009 12:19 PM Flag

    Absolute Audacity

    I am at a loss to fathom a management so delusional and arrogant who continually and consistently fails to meet objectives and deliver results YET has the unmitigated gall to ask the shareholders to: 1) rubber stamp their handpicked board, 2) authorize a horrendous increase in shares, and 3) add to the already excessive options and compensation.

    Somebody help me understand what planet these people are from, please!

    Would any reasonable person have FIRST delivered some meaningful accomplishment prior to such a proxy? It makes one question the sanity of such a management team.

    Case in point: We have seen Dendreon deliver a stellar accomplishment and they did so BEFORE they filed their 14A hence providing the shareholders something to sink their teeth into and support the proposals.

    I might also direct your attention to the DNDN filing as an example of the proper breadth and depth such a filing should contain. In comparison, EPCT's essentially says: our directors, more shares, more "incentive" compensation . . .

    The upcoming conference call next week will be the FINAL opportunity for a substantive result. A repeat of past wishy-washy platitudes will not be tolerated. You know, the usual: "we are working diligently towards finalizing our partner selection," or "we expect to quickly conclude" etc.

    If there is ANY talk that attempts to convince the shareholders to hold tight until AFTER the annual meeting, I plan to race towards the exit as fast as my feet will get me there.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
IMNP
1.91-0.09(-4.50%)11:12 AMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.